Vise Technologies’s Krystal Biotech KRYS Stock Holding History

Vise Technologies’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$351K	Hold	1,424	–	–	0.01%	1065
2025 Q4	$351K	Buy	+1,424	New	+$300K	0.01%	1071

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vise Technologies's KRYS Position: Q1 2026 in Review

Vise Technologies held its Krystal Biotech (KRYS) position steady in Q1 2026 at 1,424 shares worth $351K. The position accounts for 0.01% of the portfolio, ranked #1065.

Vise Technologies first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Vise Technologies held 1,424 shares of Krystal Biotech worth $351K as of Q1 2026.
Vise Technologies left its Krystal Biotech share count unchanged in Q1 2026.
Krystal Biotech made up 0.01% of Vise Technologies's portfolio in Q1 2026, its #1065 holding.
Vise Technologies first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.